Reduced expression of galectin-9 contributes to a poor outcome in colon cancer by inhibiting NK cell chemotaxis partially through the Rho/ROCK1 signaling pathway

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Wang, Yang ^a   Sun, Jintang ^a   Ma, Chao ^a   Gao, Wenjuan ^a   Song, Bingfeng ^a   Xue, Hao ^a   Chen, Weiliang ^a   Chen, Xi ^a   Zhang, Yun ^a   Shao, Qianqian ^a   Wang, Qingjie ^a   Zhao, Lei ^a   Liu, Jia ^a   Wang, Xiuwen ^a   Wang, Huayang ^a   Yang, Meixiang ^a   Qu, Xun ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; ECALECTIN; F ACTIN; RHO KINASE; RHO KINASE 1; UNCLASSIFIED DRUG; GALECTIN; LGALS9 PROTEIN, HUMAN; ROCK1 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CELL MIGRATION; CHEMOTAXIS; COLON CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFER; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CLINICAL TRIAL; COLON TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE; TUMOR ESCAPE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CHEMOTAXIS; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GALECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KILLER CELLS, NATURAL; MIDDLE AGED; NEOPLASM PROTEINS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR ESCAPE;

EID: 84962646941     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152599     Document Type: Article

References (51)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010; 127 (12):2893-917. doi: 10.1002/ijc.25516 PMID: 21351269
2. Board RE, Valle JW. Metastatic colorectal cancer: current systemic treatment options. Drugs. 2007; 67 (13):1851-67. PMID: 17722954
3. Markman JL, Shiao SL. Impact of the immune system and immunotherapy in colorectal cancer. Journal of gastrointestinal oncology. 2015; 6(2):208-23. doi: 10.3978/j.issn.2078-6891.2014.077 PMID: 25830040
4. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nature reviews Cancer. 2003; 3(1):55-63. PMID: 12509767
5. Koelzer VH, Lugli A, Dawson H, Hadrich M, Berger MD, Borner M, et al. CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. Journal of translational medicine. 2014; 12:81. doi: 10.1186/1479-5876-12-81 PMID: 24679169
6. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. The New England journal of medicine. 2005; 353 (25):2654-66. PMID: 16371631
7. Ling A, Edin S, Wikberg ML, Oberg A, Palmqvist R. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. British journal of cancer. 2014; 110(10):2551-9. doi: 10.1038/bjc.2014.161 PMID: 24675384
8. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997; 79 (12):2320-8. PMID: 9191519
9. Tartter PI, Steinberg B, Barron DM, Martinelli G. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Archives of surgery. 1987; 122(11):1264-8. PMID: 3675190
10. Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(4):678-89.
11. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell. 1994; 76(4):597-8. PMID: 8124704
12. Madireddi S, Eun SY, Lee SW, Nemcovicova I, Mehta AK, Zajonc DM, et al. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. The Journal of experimental medicine. 2014; 211 (7):1433-48. doi: 10.1084/jem.20132687 PMID: 24958847
13. Meggyes M, Miko E, Polgar B, Bogar B, Farkas B, Illes Z, et al. Peripheral blood TIM-3 positive NK and CD8+ T cells throughout pregnancy: TIM-3/galectin-9 interaction and its possible role during pregnancy. PloS one. 2014; 9(3):e92371. doi: 10.1371/journal.pone.0092371 PMID: 24651720
14. Nobumoto A, Oomizu S, Arikawa T, Katoh S, Nagahara K, Miyake M, et al. Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumorbearing mice. Clinical immunology. 2009; 130(3):322-30. doi: 10.1016/j.clim.2008.09.014 PMID: 18974023
15. Kasamatsu A, Uzawa K, Nakashima D, Koike H, Shiiba M, Bukawa H, et al. Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. International journal of molecular medicine. 2005; 16(2):269-73. PMID: 16012760
16. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, et al. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. International journal of cancer Journal international du cancer. 2002; 99(6):809-16. PMID: 12115481
17. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(8):2962-8.
18. Yang J, Zhu L, Cai Y, Suo J, Jin J. Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer. International journal of oncology. 2014; 45(3):1313-20. doi: 10.3892/ijo.2014.2494 PMID: 24919464
19. Li J, Liu H, Li L, Wu H, Wang C, Yan Z, et al. The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma. Oncology reports. 2013; 29(3):895-902. doi: 10.3892/or.2012.2217 PMID: 23292657
20. Starnes T, Rasila KK, Robertson MJ, Brahmi Z, Dahl R, Christopherson K, et al. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Experimental hematology. 2006; 34(8):1101-5. PMID: 16863917
21. Allavena P, Paganin C, Zhou D, Bianchi G, Sozzani S, Mantovani A. Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. Blood. 1994; 84(7):2261-8. PMID: 7919344
22. Chabot S, Kashio Y, Seki M, Shirato Y, Nakamura K, Nishi N, et al. Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology. 2002; 12(2):111-8. PMID: 11886844
23. Liang M, Ueno M, Oomizu S, Arikawa T, Shinonaga R, Zhang S, et al. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. Journal of cancer research and clinical oncology. 2008; 134(8):899-907. doi: 10.1007/s00432-008-0352-z PMID: 18264727
24. Yamauchi A, Kontani K, Kihara M, Nishi N, Yokomise H, Hirashima M. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. The breast journal. 2006; 12(5 Suppl 2):S196-200. PMID: 16959001
25. Zhang ZY, Dong JH, Chen YW, Wang XQ, Li CH, Wang J, et al. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pacific journal of cancer prevention: APJCP. 2012; 13(6):2503-9. PMID: 22938412
26. Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, Takeshita K, et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology. 2008; 18(9):735-44. doi: 10.1093/glycob/cwn062 PMID: 18579572
27. Fainaru O, Almog N, Yung CW, Nakai K, Montoya-Zavala M, Abdollahi A, et al. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2010; 24(5):1411-8.
28. Kadowaki T, Arikawa T, Shinonaga R, Oomizu S, Inagawa H, Soma G, et al. Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiate into plasmacytoid dendritic cell-like macrophages. Clinical immunology. 2012; 142(3):296-307. doi: 10.1016/j.clim.2011.11.006 PMID: 22177847
29. Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. Journal of immunology. 2008; 181(11):7660-9.
30. Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, Lee DH, et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. Journal of immunology. 2010; 185(3):1383-92.
31. Oomizu S, Arikawa T, Niki T, Kadowaki T, Ueno M, Nishi N, et al. Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion. PloS one. 2012; 7(11): e48574. doi: 10.1371/journal.pone.0048574 PMID: 23144904
32. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. The Lancet Oncology. 2009; 10(9):877-84. doi: 10.1016/S1470-2045(09)70186-X PMID: 19656725
33. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. PMID: 17008531
34. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000; 356 (9244):1795-9. PMID: 11117911
35. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000; 88(3):577-83. PMID: 10649250
36. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung cancer. 2002; 35(1):23-8. PMID: 11750709
37. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 2012; 119(13):3064-72. doi: 10.1182/blood-2011-06-360321 PMID: 22323453
38. Golden-Mason L, McMahan RH, Strong M, Reisdorph R, Mahaffey S, Palmer BE, et al. Galectin-9 functionally impairs natural killer cells in humans and mice. Journal of virology. 2013; 87(9):4835-45. doi: 10.1128/JVI.01085-12 PMID: 23408620
39. Sun J, Yang M, Ban Y, Gao W, Song B, Wang Y, et al. Tim-3 Is Upregulated in NK Cells during Early Pregnancy and Inhibits NK Cytotoxicity toward Trophoblast in Galectin-9 Dependent Pathway. PLoS One. 2016; 11(1):e0147186. doi: 10.1371/journal.pone.0147186 PMID: 26789128
40. de Kivit S, Lempsink LJ, Plants J, Martinson J, Keshavarzian A, Landay AL. Modulation of TIM-3 expression on NK and T cell subsets in HIV immunological non-responders. Clinical immunology. 2015; 156(1):28-35. doi: 10.1016/j.clim.2014.10.009 PMID: 25450337
41. Jost S, Moreno-Nieves UY, Garcia-Beltran WF, Rands K, Reardon J, Toth I, et al. Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection. Retrovirology. 2013; 10:74. doi: 10.1186/1742-4690-10-74 PMID: 23866914
42. Li YH, Zhou WH, Tao Y, Wang SC, Jiang YL, Zhang D, et al. The Galectin-9/Tim-3 pathway is involved in the regulation of NK cell function at the maternal-fetal interface in early pregnancy. Cellular & molecular immunology. 2016; 13(1):73-81.
43. Spitzenberger F, Graessler J, Schroeder HE. Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. Biochimie. 2001; 83(9):851-62. PMID: 11698107
44. Heusschen R, Freitag N, Tirado-Gonzalez I, Barrientos G, Moschansky P, Munoz-Fernandez R, et al. Profiling Lgals9 splice variant expression at the fetal-maternal interface: implications in normal and pathological human pregnancy. Biology of reproduction. 2013; 88(1):22. doi: 10.1095/biolreprod.112.105460 PMID: 23242525
45. Earl LA, Bi S, Baum LG. Galectin multimerization and lattice formation are regulated by linker region structure. Glycobiology. 2011; 21(1):6-12. doi: 10.1093/glycob/cwq144 PMID: 20864568
46. Bi S, Earl LA, Jacobs L, Baum LG. Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. The Journal of biological chemistry. 2008; 283(18):12248-58. doi: 10.1074/jbc.M800523200 PMID: 18258591
47. Lipkowitz MS, Leal-Pinto E, Cohen BE, Abramson RG. Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconjugate journal. 2004; 19(7-9):491-8. PMID: 14758072
48. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998; 279(5350):509-14. PMID: 9438836
49. Chircop M. Rho GTPases as regulators of mitosis and cytokinesis in mammalian cells. Small GTPases. 2014; 5.
50. Amano M, Nakayama M, Kaibuchi K. Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton. 2010; 67(9):545-54. doi: 10.1002/cm.20472 PMID: 20803696
51. Yamamoto H, Nishi N, Shoji H, Itoh A, Lu LH, Hirashima M, et al. Induction of cell adhesion by galectin-8 and its target molecules in Jurkat T-cells. Journal of biochemistry. 2008; 143(3):311-24. PMID: 18024965